Company profile
CELLTIUM
Pioneering first-in-class precision neurotherapeutics for Charcot-Marie-Tooth disease (CMT1A) and related neuropathies
- Industry
- Biotechnology Research
- Employees
- 1
- Headquarters
- Suwon-si, Gyeonggi-do
- Founded
- 2020
- LinkedIn followers
- 90
- Office locations
- 1
CELLTIUM company summary
CELLTIUM is a company in the Biotechnology Research industry, headquartered in Suwon-si, Gyeonggi-do, founded in 2020. On LinkedIn the company has around 1 employees and 90 followers. Its listed specialties include CMT1A, Charcot‑Marie‑Tooth disease (CMT), inherited peripheral neuropathy, rare neurological diseases, myelin regeneration.
What technology does CELLTIUM use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About CELLTIUM
Decoding neurological disease. Building medicines with precision. CELLTIUM is a biotechnology company developing precision small‑molecule neurotherapeutics, with a primary focus on Charcot‑Marie‑Tooth disease type 1A (CMT1A) and related inherited peripheral neuropathies. Our ambition is to deliver first‑in‑class, disease‑modifying therapies for patients who currently have no approved treatment options. We advance a mechanistically distinct small‑molecule pipeline designed to target core disease pathology and restore peripheral nerve function. By integrating deep disease biology with our proprietary PRECISION™ platform, we capture high‑content phenotypic data across large compound libraries. This unique biological dataset powers our AI/ML engine to generate actionable phenomic signatures and guide the discovery of clinical candidates with strong translational potential. Our lead program, CTM26, is a first‑in‑class small molecule for CMT1A designed to address core disease biology and restore peripheral nerve function, based on compelling preclinical data in disease‑relevant models. CELLTIUM actively collaborates with leading global patient advocacy groups and research foundations in the CMT space to validate our therapeutic assets and accelerate clinical translation. We are open to strategic partnerships in co‑development, licensing, and investment with global biopharma and investors who share our commitment to rare neurological diseases.
Specialties
Where is CELLTIUM located?
CELLTIUM lists 1 location.
Compare companies similar to CELLTIUM
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
CELLTIUM celltium.com | Biotechnology Research | 1 | 2020 | Suwon-si, Gyeonggi-do |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about CELLTIUM
What does CELLTIUM do?
Decoding neurological disease. Building medicines with precision. CELLTIUM is a biotechnology company developing precision small‑molecule neurotherapeutics, with a primary focus on Charcot‑Marie‑Tooth disease type 1A (CMT1A) and related inherited peripheral neuropathies. Our ambition is to deliver first‑in‑class, disease‑modifying therapies for patients who currently have no approved treatment options. We advance a mechanistically distinct small‑molecule pipeline designed to target core disease pathology and restore peripheral nerve function. By integrating deep disease biology with our proprietary PRECISION™ platform, we capture high‑content phenotypic data across large compound libraries. This unique biological dataset powers our AI/ML engine to generate actionable phenomic signatures and guide the discovery of clinical candidates with strong translational potential. Our lead program, CTM26, is a first‑in‑class small molecule for CMT1A designed to address core disease biology and restore peripheral nerve function, based on compelling preclinical data in disease‑relevant models. CELLTIUM actively collaborates with leading global patient advocacy groups and research foundations in the CMT space to validate our therapeutic assets and accelerate clinical translation. We are open to strategic partnerships in co‑development, licensing, and investment with global biopharma and investors who share our commitment to rare neurological diseases.
How many employees does CELLTIUM have?
CELLTIUM has around 1 employees on LinkedIn.
Where is CELLTIUM headquartered?
CELLTIUM is headquartered in Suwon-si, Gyeonggi-do.
When was CELLTIUM founded?
CELLTIUM was founded in 2020.
Build a lead list from companies like CELLTIUM
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.